Document is current
Any future updates will be listed below
-
Authors
Wang, Zixiang
Wang, Bingyu
Feng, Yuan
Ye, Jinwen
Mao, Zhonghao
Zhang, Teng
Xu, Meining
Zhang, Wenjing
Jiao, Xinlin
Zhang, Qing
Zhang, Youzhong
Cui, Baoxia https://orcid.org/0000-0001-9088-1240
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04516616 at ClinicalTrials.govnct04516616 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial
https://doi.org/10.1136/bmjopen-2022-067767
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.5520
EP047/#376 Multi-omics characterization of cellular state diversity and bidirectional tumor-stroma/immune interactions in cervical squamous cell carcinoma
https://doi.org/10.1136/ijgc-2023-igcs.166
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
https://doi.org/10.1136/jitc-2024-009024
nct04799639 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial
https://doi.org/10.1136/bmjopen-2022-067767
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.5520
EP047/#376 Multi-omics characterization of cellular state diversity and bidirectional tumor-stroma/immune interactions in cervical squamous cell carcinoma
https://doi.org/10.1136/ijgc-2023-igcs.166
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
https://doi.org/10.1136/jitc-2024-009024
nct04238988 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.5512
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
https://doi.org/10.1136/jitc-2024-009024
Documents that mention this clinical trial
Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature review
https://doi.org/10.1136/ijgc-2023-004928
Cervical cancer: a new era
https://doi.org/10.1136/ijgc-2024-005579
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
https://doi.org/10.1136/jitc-2024-009024
-
Funding
Funding for this research was provided by:
National Key Research and Development Program of China (2021YFC2701203)
National Key Research and Development Program of China (2022YFC2704401)
National Natural Science Foundation of China (82103425)
National Natural Science Foundation of China (82172940)
National Natural Science Foundation of China (82303055)
Natural Science Foundation of Shandong Province (ZR2021QH187)
Natural Science Foundation of Shandong Province (ZR2023QH312)
- License Information
